MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. The company focuses on developing its novel tri-specific Nanobody Sonelokimab (SLK), an IL-17A and IL-17F inhibitor, in multiple inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
$14.56 +0.56 (4.00%)
As of 02/08/2023 15:58:45 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.